2024-03-07 12:29:03 ET
EyePoint Pharmaceuticals, Inc. (EYPT)
Q4 2023 Earnings Conference Call
March 07, 2024, 08:30 AM ET
Company Participants
George Elston - EVP and CFO
Jay Duker - President and CEO
Ramiro Ribeiro - Chief Medical Officer
Conference Call Participants
Tessa Romero - JPMorgan
Tyler Van Buren - TD Cowen
Yatin Suneja - Guggenheim
Jennifer Kim - Cantor Fitzgerald
Graig Suvannavejh - Mizuho Securities
Colleen Kusy - Baird
Yale Jen - Laidlaw & Company
Yi Chen - H.C. Wainwright
Presentation
Operator
Good morning. My name is Kevin and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Development Conference Call. There will be a question-and-answer session to follow at the completion of the prepared remarks. Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to George Elston, Executive Vice President and Chief Financial Officer of EyePoint Pharmaceuticals.
George Elston
Thank you and thank you all for joining us on today’s conference call to discuss EyePoint Pharmaceuticals fourth quarter and full year 2023 financial results and recent corporate developments. With me today is Dr. Jay Duker, President and Chief Executive Officer. Jay will begin with a review of recent corporate updates and discuss the ongoing clinical trials for EYP-1901. I will close with commentary on the fourth quarter and full year 2023 financial results. We will then open the call for your questions.
Earlier this morning, we issued a press release detailing our financial results and recent operational developments. A copy of the release can be found in the Investor Relations tab on the corporate website, www.eyepointpharma.com....
Read the full article on Seeking Alpha
For further details see:
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript